Ellogon AI was founded by Evangelos Kanoulas and Efstratios Gavves in 2019, with a focus on computational pathology and personalized immunotherapy with AI. After a year of working to get the company up and running, the Ellogon AI team welcomed their first employee in February 2021.The team grew fast to 9 full-time employees and continues to expand.
According to Gavves, Ellogon AI co-founder, “the goal is to use AI to quantify biomarkers that are predictive for immunotherapy outcome, and thereby support the selection of cancer patients that will benefit from the treatment. We got this idea by carefully analyzing the potential impact of a successful AI model versus the difficulty of doing this manually. To select patients, medical experts will evaluate digitized whole slide images of tumor tissue, which is basically a Sisyphean task due to the extreme complexity of cancer biology. AI algorithms are excellent in analyzing gigapixel images, which made digitized tissue images the natural domain to apply.”
With ELISE funding Ellogon AI will hire an AI engineer to incorporate geometry into their deep learning models. This is an important aspect, considering that geometry is essential in computational pathology, where the patterns have a specific structure. “The obtained algorithms will improve the efficiency and effectiveness in quantifying biomarkers. Consequently, medical experts will be able to improve their selection of patients that can benefit from immunotherapy and other patients can be spared the undesirable side effects of the treatment. This will improve the overall survival and quality of life of patients, and decrease the economic burden of the therapy”, says Gavves.
Interested to learn more?
Website: https://ellogon.ai/
Contact: Efstratios Gavves (egavves@ellogon.ai)
More about the ELISE 1st Open call and awarded companies is available here.
